Altogether, these findings open a novel scenario for targeting c-MYC transcription, and it would be of the highest importance to check whether such an AMBRA1 dependence could be detected in other different c-MYC-driven tumours, such as leukaemia or gliomas [43, 80]. The gene discussed is AMBRA1; the disease is glioma.